Editas Medicine (EDIT) Projected to Announce Earnings on Monday

Key Points

• Editas Medicine is expected to report Q3 2026 results before the market opens on November 9. Analysts forecast a loss of $0.21 per share and revenue of $4.54 million, with the earnings call scheduled for November 10 at 4:00 p.m. ET.
• In its previous quarter, Editas reported a loss of $0.15 per share, beating estimates for a $0.27 loss, while revenue of $11.89 million exceeded the $2.85 million consensus estimate. Analysts expect full-year and next-year losses of $0.80 and $0.81 per share, respectively.
• Wall Street’s consensus rating is “Moderate Buy,” based on six Buy ratings and one Sell rating, with an average price target of $5.83 versus the stock’s recent $2.67 price. Recent upgrades from Guggenheim and Wells Fargo set targets of $5 and $6.

Editas Medicine (NASDAQ:EDIT - Get Free Report) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $4.54 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%. The firm had revenue of $11.89 million for the quarter, compared to analyst estimates of $2.85 million. On average, analysts expect Editas Medicine to post ($0.80) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

Editas Medicine Stock Performance

Shares of NASDAQ:EDIT opened at $2.67 on Monday. The company has a market capitalization of $410.06 million, a P/E ratio of -3.56 and a beta of 2.00. Editas Medicine has a 52-week low of $1.66 and a 52-week high of $3.94. The company has a 50-day simple moving average of $2.76 and a 200 day simple moving average of $2.67.

Wall Street Analysts Forecast Growth

EDIT has been the topic of a number of recent research reports. Guggenheim upgraded Editas Medicine from a "neutral" rating to a "buy" rating and set a $5.00 target price on the stock in a research note on Wednesday, September 23rd. Wells Fargo & Company upgraded Editas Medicine from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $4.00 to $6.00 in a research report on Thursday, October 8th. Weiss Ratings upgraded Editas Medicine from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. LADENBURG THALM/SH SH assumed coverage on shares of Editas Medicine in a report on Tuesday, August 18th. They set a "buy" rating and a $6.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Editas Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $5.83.

Editas Medicine Company Profile

Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines using CRISPR-based gene-editing technologies. The company's research platforms include CRISPR/Cas9 and CRISPR/Cas12a, which are designed to make precise changes to DNA and potentially treat diseases caused by genetic abnormalities.

Editas Medicine's lead investigational program is reni-cel, formerly known as EDIT-301. Reni-cel is an ex vivo gene-editing therapy intended to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient's blood-forming stem cells before they are returned to the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.